ACE and cardiomyopathy: Early initiation of angiotensin-converting enzyme (ACE) inhibitors slows the progression of the cardiomyopathy (Duboc et al., 2005, 2007; Silva et al., 2017), and cardiomyopathy treatment and heart failure management in DMD largely relies on guideline-directed heart failure strategies (Buddhe et al., 2018; Feingold et al., 2017; McNally et al., 2015; Yancy et al., 2017).